S-1/A: Picard Medical Files S-1/A for IPO, Highlighting Total Artificial Heart Dominance Amidst Significant Losses and Going Concern Warning

Picard Medical, a medical technology company specializing in the SynCardia Total Artificial Heart, is pursuing an initial public offering to raise $17 million, despite a history of substantial operating losses and a 'going concern' warning from its auditors.

Summary

• Picard Medical, Inc. is a holding company that owns SynCardia Systems, LLC, which manufactures and sells the only U.S. FDA and Health Canada approved implantable total artificial heart (SynCardia TAH).
• The company is offering 4,250,000 shares of common stock in its initial public offering, with an estimated price range of $3.50 to $4.50 per share, aiming for a midpoint of $4.00 per share.
• Net proceeds from the offering are estimated to be approximately $15.4 million, which will be used for market expansion in China, R&D for new products, building sales and marketing capabilities, and repaying debt.
• Picard Medical has incurred significant net losses, including $21.1 million in 2024 and $15.6 million in 2023, and $5.6 million for the three months ended March 31, 2025.
• The company's independent registered public accounting firm has included an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• Hunniwell Picard I, LLC will control 54.8% of the outstanding common stock after the IPO, making Picard Medical a controlled company and allowing it to rely on certain NYSE American corporate governance exemptions.
• The SynCardia TAH has been implanted in over 2,100 patients across 27 countries and is an established bridge to heart transplantation for biventricular failure.
• Future product development includes the fully implantable Emperor Total Artificial Heart (expected FDA approval in 2028), an upgraded portable Freedom+ Driver (expected FDA approval by H2 2025), and next-generation Freedom and C2 Drivers (expected FDA approvals in H2 2026 and H2 2027, respectively).
• The company is seeking to expand the SynCardia TAH's indication for use from 'Bridge to Transplantation' (BTT) to 'Bridge to Candidacy' (BTC) and for long-term use (2 years or more), with an FDA answer on BTC expected in Q2 2026.
• Picard Medical voluntarily cancelled its EU CE mark in July 2022 due to post-market surveillance deficiencies under MDD and plans to reapply for an MDR CE mark in Q4 2025.
• A field correction was initiated for cannula tears in the SynCardia TAH, with 104 reports but zero Serious Adverse Events as of March 20, 2025; a design change submission to FDA is expected in Q3 2025.
• The company plans to invest $2.85 million to fund SynCardia Medical (Beijing), Inc. for distribution rights in China, contingent on becoming publicly traded.
• Carmat SA, a direct competitor, recently filed for insolvency and was placed into receivership in France, potentially reducing competition.
• The company relies on single-source suppliers for crucial components of its drivers and valves, posing a supply chain risk.
• As of March 31, 2025, the company had cash and cash equivalents of $688,000 and a total liabilities of $40.62 million, including $15.48 million in convertible notes payable and $9.11 million in derivative liabilities.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant and worsening financial losses, a 'going concern' warning from auditors, substantial revenue decline, and a large working capital deficit. While the company has a unique FDA-approved product and a promising pipeline, the severe financial distress and reliance on future capital raises for survival outweigh the positive product developments and competitive advantages.

Positives

• SynCardia TAH is the only U.S. FDA and Health Canada approved implantable total artificial heart, providing a significant competitive advantage.
• Over 2,100 SynCardia TAHs have been implanted in patients across 27 countries, demonstrating extensive clinical experience and established market presence.
• The company has a clear product development roadmap, including a fully implantable TAH (Emperor), and upgraded portable and hospital drivers (Freedom+, Unicorn, Companion 3).
• FDA approved the removal of 'temporary' and '-t' from the SynCardia TAH Indications for Use (IFU) and product name on November 25, 2024, simplifying its designation.
• Discussions with FDA are ongoing to expand the SynCardia TAH's IFU to include 'Bridge to Candidacy' (BTC) and long-term use (24 months or more), potentially broadening market reach.
• The upgraded Freedom+ Driver is anticipated to substantially reduce false alarm rates and servicing costs, improving patient quality of life and operational efficiency.
• Prototypes for the next-generation Unicorn driver and fully implantable Emperor TAH have shown promising results in bench testing, exceeding minimum cardiac output requirements and demonstrating high durability and low energy consumption.
• The Emperor TAH technology has extensive intellectual property coverage, including newly awarded U.S. patents No. 11,918,798 and No. 12,121,711 B2, and China patent CN 115279450 B.
• The company's proprietary Segmented Polyurethane Solution (SPUS) for heart ventricles is FDA approved and has extensive clinical experience, presenting a significant barrier to competitors.
• CMS approved implant procedures using the SynCardia TAH as eligible for DRG 001, the highest possible reimbursement, with private insurers also providing coverage.
• Carmat SA, a direct competitor, filed for insolvency and was placed into receivership in France on June 30, 2025, potentially reducing future competition in the TAH market.
• The company has a successful clinical training and education program, with over 30 certified centers and 30 centers that have completed at least one implant in the last 36 months.
• Integrated manufacturing processes under ISO 13485-certified quality management system allow for in-house production and rigorous testing, with no deficiencies noted in the latest MDSAP audit in November 2024.
• The company is actively increasing its presence on social media and interacting with heart failure patients and their families through outreach programs.

Negatives

• The company has a history of significant operating losses, including $21.1 million in 2024 and $5.6 million for the three months ended March 31, 2025.
• The independent registered public accounting firm has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and a net capital deficiency.
• Total revenues decreased by 13% in 2024 compared to 2023, and by 69% for the three months ended March 31, 2025, compared to the same period in 2024, driven by declines in both U.S. and foreign sales.
• The company's total cost of revenue as a percentage of total sales was 158% for the three months ended March 31, 2025, indicating significant unprofitability at the gross margin level.
• The company relies on specialized single-source suppliers (Bimba, Heitek Automation) for crucial components of its drivers and SynHall Valves, posing a significant supply chain risk if these relationships cease or suppliers fail.
• The company voluntarily cancelled its EU CE mark in July 2022 due to post-market surveillance deficiencies under MDD, limiting its ability to market or sell products in European markets until MDR certification is obtained.
• Many aspects of the SynCardia TAH are no longer protected by patents, relying primarily on trade secrets, which are vulnerable to misappropriation or becoming publicly known.
• The company has significant customer concentrations, with Customer A accounting for 49% of revenue in Q1 2025, making it vulnerable to changes in purchasing policies or loss of key customers.
• The company does not intend to pay cash dividends for the foreseeable future, which may deter certain investors.
• The company will incur increased costs and demands upon management as a result of complying with laws and regulations affecting public companies.
• The company's common stock has no prior public market, and its stock price may be volatile and decline after the offering.
• Stockholders may be subject to significant dilution from the conversion of preferred shares and convertible notes, as well as future capital raises.
• The company has a significant working capital deficit of $30.435 million as of March 31, 2025.
• As of March 31, 2025, $3.7 million of 2024 Convertible Notes and $7.0 million of aggregated convertible notes (donated to Nexus and Another Dimension) are past due, and the company is working with lenders to extend maturity dates.

Risks

• History of significant losses and inability to achieve and sustain profitability, leading to substantial doubt about continuing as a going concern.
• Reliance on a limited number of products (SynCardia TAH) for substantially all revenue, making the business vulnerable to declines in sales or failure to gain market acceptance.
• Manufacturing of SynCardia TAH requires highly specialized knowledge and operator skills, and the loss of key personnel or inability to scale production could adversely impact operations.
• Dependence on specialized single-source suppliers for critical components (e.g., Bimba/Heitek Automation for driver components, SynHall Valves), with no second-source suppliers for many, risking production delays or stoppages.
• Future success depends on timely development and regulatory approval of new products or enhancements, which is a lengthy, expensive, and unpredictable process.
• Inability to successfully complete pre-clinical studies or clinical trials for new products or expanded indications could limit regulatory approvals.
• Uncertainty regarding continued adequate coverage and reimbursement from third-party payors (government and private) for product use, which is critical for market acceptance.
• Changes in U.S. and international trade policies, particularly with respect to China, could adversely impact business and operating results.
• Failure to reinstate the CE certificate under CE MDR could materially adversely affect the ability to market or sell products in European markets.
• Prior weaknesses in compliance with post-market surveillance requirements under CE MDD may limit future market access in Europe.
• Many aspects of the SynCardia TAH are no longer protected by patents, increasing vulnerability to competition if trade secrets or know-how are misappropriated or become publicly known.
• Exposure to extensive patent and intellectual property litigation in the medical device industry, which could be costly, divert management attention, or prevent product marketing.
• Risk of product liability claims and other damage claims due to inherent risks in implantable life-sustaining medical devices, including potential misuse by physicians.
• Product deficiencies could result in field actions, recalls, substantial costs, and harm to reputation, as evidenced by the ongoing cannula tear issue.
• International operations subject the company to various operating risks, including difficulties in enforcing IP rights, pricing pressure, and political/economic instability.
• Subject to credit risk from accounts receivable, particularly from foreign customers in economically unstable regions.
• Exposure to risks associated with currency fluctuations, which could impact results of operations.
• Changes in U.S. and foreign tax laws could materially adversely affect business, cash flow, and financial condition.
• Ability to use net operating loss carryforwards and other tax attributes may be subject to limitations due to ownership changes.
• The demand for total artificial hearts could decrease due to medical advances providing better or less invasive alternatives.
• Failure to protect information technology infrastructure against cyber-based attacks, network security breaches, or data corruption could disrupt operations and endanger patient safety.
• As a controlled company, stockholders may not have the same protections afforded to stockholders of companies subject to full corporate governance requirements.
• Exclusive forum provisions in the charter could limit stockholders' ability to bring claims in preferred judicial forums and increase costs.

Future Outlook

The company's future vision is to develop the world's first fully implantable SynCardia TAH (Emperor) as an alternative to heart transplantation, with expected FDA approval in 2028. Near-term product developments focus on innovating current driver technology to expand the SynCardia TAH's indication for use from Bridge to Transplantation (BTT) to Bridge to Candidacy (BTC) and for long-term use of two years or more. The company also plans to expand product sales into more international markets. FDA approval for the upgraded Freedom+ Driver is anticipated by the second half of 2025, and next-generation Freedom and C2 Drivers are expected to gain FDA approvals during the second halves of 2026 and 2027, respectively. The Unicorn driver system is expected to complete regulatory testing in the second half of 2026, with FDA approval anticipated around mid-2027.

Management Comments

• Patrick NJ Schnegelsberg, CEO, has over 25 years of executive leadership experience in the medical device sector.
• Richard Fang, Director and managing partner of Hunniwell Lake Ventures LLC, believes in the 'ironman heart' and envisions the SynCardia TAH as a preferred alternative to heart transplant.
• Management acknowledges significant issues with the company's regulatory compliance regime following a change of control in 2021 and is actively working to solve these issues.
• Management believes that existing cash and cash equivalents as of March 31, 2025, and anticipated expenditures will not enable funding operations for the next twelve months, necessitating additional financing.
• Management believes that, based on the company's technology, intellectual property, know-how, and extensive human clinical experience, it has significant advantages over other companies developing other TAH products.

Industry Context

The company operates in the cardiovascular medical device industry, specifically focusing on total artificial hearts (TAH) for end-stage heart failure patients. Cardiovascular disease is the leading cause of death globally, with 6.8 million people suffering from heart failure in the U.S. and 56.2 million worldwide. Heart transplantation is the treatment of choice, but demand far exceeds supply (over 7,500 patients on the U.S. transplant list). The SynCardia TAH is currently the only FDA and Health Canada approved TAH, giving it a unique market position. Competitors like Carmat SA (Aeson device) have faced significant challenges, including insolvency, while BiVACOR, Inc. is in early-stage human clinical testing. The market also includes Left Ventricular Assist Devices (LVADs) and temporary Mechanical Circulatory Support (MCS) devices, which are more commonly used but do not replace both ventricles or allow for patient discharge like the SynCardia TAH. The global market for heart implants is substantial, with large patient populations in the EU, India, China, and the Middle East, indicating significant international expansion opportunities.

Comparison to Industry Standards

• SynCardia TAH is the only total artificial heart approved for commercial use in the United States and Canada for the Bridge to Transplantation (BTT) indication, distinguishing it from competitors like Carmat (Aeson) and BiVACOR.
• Carmat's Aeson device obtained CE mark in Europe in December 2020 but is currently undergoing re-certification under MDR and has faced quality and software issues, leading to insolvency filings in June 2025, indicating a significant competitive setback for Carmat.
• BiVACOR's total artificial heart is in early-stage human clinical testing (5 of 20 patients enrolled in EFS as of March 2025) and has not obtained approval for any market to date, positioning SynCardia as significantly more advanced in commercialization.
• The SynCardia TAH (70cc implant) generates cardiac output up to 10.5 liters per minute, and the 50cc implant up to 7.5 liters per minute, which compares favorably to a normal human heart's average cardiac output of 5.6 liters per minute.
• The SynCardia TAH replaces both left and right ventricles and all four heart valves, allowing patients to be discharged, unlike LVADs or temporary MCS devices (e.g., Abbott HeartMate 3, Abiomed Impella, Getinge CardioHelp) which typically support only one ventricle, are for hospital use only, or are temporary.
• Reimbursement for SynCardia TAH under DRG 001 in the U.S. ranges from $203,560 to $478,942 (mean: $296,685), which is comparable to LVADs (also DRG 001) but significantly higher than ECMO devices (DRG 003, average $170,000) or temporary axial flow assist devices (DRG 215/221, average $90,000/$40,000).
• The SynCardia TAH implant weight is 250g, significantly lighter than Carmat's Aeson (900g) and BiVACOR (650g), potentially offering advantages for patient fit and comfort.
• The SynCardia TAH implant volume (250-400ml) is smaller than Carmat's Aeson (750ml), allowing it to serve men, women, and children, whereas Aeson may not fit all patients.
• SynCardia has over 2,100 implants to date, far exceeding Carmat (108 implants as of July 2025) and BiVACOR (6 implants as of March 2025), demonstrating superior clinical experience and track record.
• Neurological event rates in real-world data for SynCardia TAH patients (5% of total adverse events) compare favorably to the PMA FDA study (27% for all implanted patients, 5% for per-protocol patients).

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal matters or claims as of the date of the prospectus.
• The company may become party to legal matters and claims in the ordinary course of business in the future, but does not anticipate a material adverse impact on financial position, results of operations, or cash flows from their resolution.
• The company issued an urgent field safety notice on February 17, 2023, regarding potential cannula tears in the SynCardia TAH, which is part of an FDA Class 2 recall under Part 806. As of March 20, 2025, there have been 104 reports of cannula tears but zero Serious Adverse Events associated with them.

Related Party Transactions

• On July 2, 2023, Picard Medical, Inc. agreed to purchase a majority ownership (60% equity for $2.85 million) of SynCardia Medical (Beijing), Inc., contingent on Picard Medical becoming publicly traded. This entity is responsible for registration, sale, and distribution of SynCardia TAH in China.
• Hunniwell Picard I, LLC, a manager-managed venture capital fund, controls 54.8% of the outstanding common stock post-IPO and is managed by Yuncai (Richard) Fang, Sinyew (Daniel) Teo, and Chris Hsieh, who also hold director positions or are nominees.
• Richard Fang, a director, and Fang Family Fund, LLC and Fang Family Fund II, LLC (entities affiliated with Richard Fang) have provided numerous loans to the company, totaling approximately $7.0 million consolidated into a convertible note on July 2, 2024.
• On November 12, 2024, Richard Fang donated the $7.0 million aggregated convertible note and related accrued interest to two unrelated not-for-profit organizations, Nexus Science Foundation Inc. and Another Dimension Foundation, which will each receive 50% of the converted value in registered shares.
• As of March 31, 2025, the Nexus and Another Dimension notes are past due, and the company is working with lenders to extend their maturity dates.
• On July 1, 2025, the company amended a $250,000 related party working capital loan from Hunniwell (issued August 20, 2024) and issued new loans of $93,633 to Hunniwell (for travel expense reimbursements) and $187,190 to Daniel Teo (for severance from prior employment) under the same Senior Secured Notes terms, with a modified maturity date of October 15, 2025.
• On July 8, 2025, the company borrowed $425,000 from Fang Family Fund I, LLC, due October 15, 2025, under Senior Secured Notes terms.
• As of March 31, 2025, the company had $112,000 due from Versa Capital Management, LLC, a related party, under an unsecured promissory note from September 2021, which has not been collected.
• In December 2022, 5,550,000 shares of Series A-1 Preferred Stock were issued for payment in kind of $5.6 million in notes payable, and 791,857 shares were sold for $2.65 million cash proceeds, with Hunniwell Picard I being the owner of all outstanding Preferred Stock.
• On July 7, 2025, Hunniwell exercised the option to convert all of its preferred stock to 39,618,919 shares of common stock.

Stakeholder Impact

• **Shareholders (Existing & New):** Existing shareholders will experience significant dilution from the IPO and conversion of preferred stock and convertible notes. New investors will face immediate dilution. The 'controlled company' status means Hunniwell will effectively determine all matters requiring shareholder approval, limiting influence for other shareholders. The company's going concern risk poses a significant threat to investment value.
• **Employees:** The company has over 75 employees and is increasing sales specialists. Continued operating losses and the 'going concern' warning could impact job security or future compensation. Stock-based compensation plans are in place, but their value is tied to the company's stock performance.
• **Customers (Hospitals & Surgeons):** The company's products are critical for end-stage heart failure patients. Supply chain risks due to single-source suppliers could impact product availability. Regulatory issues (e.g., EU CE mark cancellation, cannula tears) could affect product confidence and usage. The company's financial instability could raise concerns about long-term product support and maintenance.
• **Suppliers:** The company's reliance on single-source suppliers for critical components means these suppliers are crucial to the company's operations. Financial difficulties at Picard Medical could impact its ability to pay suppliers or maintain relationships.
• **Creditors:** The company has substantial debt, including related party loans and convertible notes, some of which are past due. The 'going concern' warning indicates a high risk for creditors regarding repayment.

Next Steps

• Complete the initial public offering and list shares on the NYSE American under the symbol PMI.
• Utilize net IPO proceeds to fund market expansion in China, research and development activities for new products (Emperor, Freedom+, Unicorn, Companion 3), build sales and marketing capabilities, and repay debt.
• Continue efforts to address post-market surveillance deficiencies and update documentation to align with MDR requirements for reapplication of CE mark in Q4 2025.
• Await FDA's answer regarding the 180-day PMA supplement for expanded indications (removing 'imminent death' and adding 'Bridge to Candidacy') in Q2 2026.
• Gather additional clinical data (at least 50 patients supported for 24 months or more) to support the long-term use indication for SynCardia TAH.
• Submit design changes to the FDA via a 180-Day PMA Supplement in Q3 2025 to address cannula tears.
• Conduct first-in-animal trials for the fully implantable Emperor Total Artificial Heart in the second half of 2026.
• Develop the Unicorn driver working prototype into a testable commercial product and complete regulatory testing in H2 2026, with FDA submission expected as a 180-day PMA supplement.
• Work with lenders to extend the maturity dates of currently past-due convertible notes.
• Appoint additional independent directors to the Board to meet NYSE American listing rules for audit and compensation committee composition within the phase-in period.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by substantial and increasing net losses, a significant working capital deficit, and an explicit 'going concern' warning from its auditors. Revenue has sharply declined, and gross margins are negative. While the company possesses a unique FDA-approved product and a promising R&D pipeline, its current financial state indicates an unsustainable burn rate and a high probability of requiring further dilutive financing or facing operational curtailment. The reliance on related party loans, some of which are past due, highlights a precarious liquidity position. The loss of the EU CE mark and the unpredictable nature of FDA approvals for pipeline products add significant regulatory uncertainty. The competitive landscape, while seeing a major competitor (Carmat) file for insolvency, still presents challenges from other emerging players. Given the profound financial instability, high operational risks, and the explicit 'going concern' warning, the stock presents an extremely high-risk investment with a strong likelihood of further value erosion. A seasoned investor would prioritize capital preservation and avoid such a speculative investment.

Keywords

Total Artificial Heart, SynCardia, Medical Device, Heart Failure, Cardiovascular, FDA Approval, IPO, Biotechnology, Implantable Devices, Cardiac Replacement, Bridge to Transplant, Mechanical Circulatory Support, Controlled Company, Going Concern, Product Development, Regulatory Approval, Intellectual Property, Healthcare, Medical Technology